The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•8 April 2026•

1 min read

MedwellAI Enters Final Due Diligence for Apollo Biowellness Acquisition

Key Facts

1MedwellAI (MWAI) is reviewing final due diligence to acquire Apollo Biowellness (KOAN) and its subsidiaries.

2MedwellAI has reserved a Preferred Series B class of stock for the share exchange and assumption of certain Apollo liabilities.

3Negotiations are ongoing with Apollo's secured creditors and debtholders, which must be resolved prior to closing the transaction.

MedwellAI (MWAI) has announced it is currently reviewing the final due diligence for its planned acquisition of Apollo Biowellness (KOAN) and its subsidiaries. As part of the transaction structure, MedwellAI has reserved a Preferred Series B class of stock to facilitate the share exchange and the assumption of certain Apollo liabilities. However, the completion of the acquisition remains contingent on the resolution of ongoing negotiations with Apollo’s secured creditors and debtholders. These discussions are considered a critical prerequisite that must be resolved before the transaction can officially close. While the process is moving forward, the requirement for creditor approval introduces a level of uncertainty regarding the final closing timeline. Investors in the OTC markets are closely monitoring these developments for their impact on the combined entity's future balance sheet.